Literature DB >> 8570020

Enzymes and inhibitors in leu-enkephalin in metabolism in human plasma.

F Bolacchi1, M Marini, A Urbani, L G Roda.   

Abstract

The enzymes degrading leucine enkephalin in human plasma and the inhibitors active on these enzymes were studied by kinetic and chromatographic techniques. Data obtained evidence the existence of complex kinetics of leu-enkephalin hydrolysis and of formation of its hydrolysis by-products. These appear to originate from the combined effect of further hydrolysis of the enkephalin's fragments after their release and of competition between the different enzymes present in plasma. Chromatographic separation of plasma proteolysis inhibitors indicates the existence of several pools of substances acting on all three enzyme groups that degrade leu-enkephalin. The partial specificity of these substances induces competition effects: consequently, the actual protection over leu-enkephalin is considerably lower that the total inhibitory activity. That notwithstanding, plasma inhibitors control enkephalin hydrolysis to a relevant extent, while they modify only slightly the ratio of hydrolysis between the different enzymes. This latter parameter--and specifically the large prevalence of aminopeptidases over dipeptidylaminopeptidases and dipeptidylcarboxypeptidases--appears controlled mainly by kinetic factors.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8570020     DOI: 10.1007/bf00995551

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  34 in total

1.  Hydrolysis and protection from hydrolysis of enkephalins in human plasma.

Authors:  M Marini; G Roscetti; L Bongiorno; A Urbani; L G Roda
Journal:  Neurochem Res       Date:  1990-01       Impact factor: 3.996

2.  Immunomodulatory and therapeutic properties of bestatin in mice.

Authors:  J E Talmadge; B F Lenz; R Pennington; C Long; H Phillips; M Schneider; H Tribble
Journal:  Cancer Res       Date:  1986-09       Impact factor: 12.701

3.  Surface aminopeptidase activity of human lymphocytes. I. Biochemical and biologic properties of intact cells.

Authors:  A A Amoscato; J W Alexander; G F Babcock
Journal:  J Immunol       Date:  1989-02-15       Impact factor: 5.422

Review 4.  Biological inactivation of enkephalins and the role of enkephalin-dipeptidyl-carboxypeptidase ("enkephalinase") as neuropeptidase.

Authors:  J C Schwartz; B Malfroy; S De La Baume
Journal:  Life Sci       Date:  1981-10-26       Impact factor: 5.037

5.  Met-enkephalin circulates in human plasma.

Authors:  V Clement-Jones; P J Lowry; L H Rees; G M Besser
Journal:  Nature       Date:  1980-01-17       Impact factor: 49.962

6.  Experience-dependent regulation of Leu-enkephalin hydrolysis in rat plasma.

Authors:  G Schulteis; J L Martinez
Journal:  Peptides       Date:  1993 Mar-Apr       Impact factor: 3.750

7.  The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice.

Authors:  B P Roques; M C Fournié-Zaluski; E Soroca; J M Lecomte; B Malfroy; C Llorens; J C Schwartz
Journal:  Nature       Date:  1980-11-20       Impact factor: 49.962

8.  Inhibition of enkephalin degradation attenuated stress-induced motor suppression (conditioned suppression of motility).

Authors:  T Nabeshima; A Katoh; T Kameyama
Journal:  J Pharmacol Exp Ther       Date:  1988-01       Impact factor: 4.030

9.  Effect of human endopeptidase 24.11 ("enkephalinase") on IL-1-induced thymocyte proliferation activity.

Authors:  M E Pierart; T Najdovski; T E Appelboom; M M Deschodt-Lanckman
Journal:  J Immunol       Date:  1988-06-01       Impact factor: 5.422

10.  Involvement of endopeptidase-24.11 in degradation of substance P by glioma cells.

Authors:  S Endo; H Yokosawa; S Ishii
Journal:  Neuropeptides       Date:  1989-10       Impact factor: 3.286

View more
  2 in total

1.  Role of enzymes and inhibitors in leu-enkephalin metabolism in rabbit and human plasma.

Authors:  F Bolacchi; M Marini; A Urbani; L Bongiorno; L G Roda
Journal:  Neurochem Res       Date:  1996-08       Impact factor: 3.996

2.  An Effective and Safe Enkephalin Analog for Antinociception.

Authors:  K K DurgaRao Viswanadham; Roland Böttger; Lukas Hohenwarter; Anne Nguyen; Elham Rouhollahi; Alexander Smith; Yi-Hsuan Tsai; Yuan-Yu Chang; Christopher Llynard Ortiz; Lee-Wei Yang; Liliana Jimenez; Siyuan Li; Chan Hur; Shyh-Dar Li
Journal:  Pharmaceutics       Date:  2021-06-22       Impact factor: 6.321

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.